We are live on ! Find out more
PRAX icon

Praxis Precision Medicines
PRAX

60 hedge funds and large institutions have $179M invested in Praxis Precision Medicines in 2023 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 32 increasing their positions, 13 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

25,100% more call options, than puts

Call options by funds: $252K | Put options by funds: $1K

146% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 13

87.8% more ownership

Funds ownership: 5.93% → 93.73% (+88%)

9% less capital invested

Capital invested by funds: $196M → $179M (-$16.7M)

19% less funds holding

Funds holding: 74 → 60 (-14)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

58% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 24

Holders
60
Holders Change
-14
Holders Change %
-18.92%
% of All Funds
0.87%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
10
Increased
32
Reduced
13
Closed
24
Calls
$252K
Puts
$1K
Net Calls
+$251K
Net Calls Change
+$106K

Top Buyers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$2.76M
2
Verition Fund Management
Verition Fund Management
Connecticut
+$1.78M
3
PHS
PFM Health Sciences
California
+$1.11M
4
CIBC Asset Management
CIBC Asset Management
Ontario, Canada
+$939K
5
IC
Ikarian Capital
Texas
+$901K

Top Sellers

1
VVA
Vida Ventures Advisors
Massachusetts
-$2.51M
2
SCM
Soleus Capital Management
Connecticut
-$1.97M
3
TLP
Tri Locum Partners
New York
-$1.35M
4
ACM
Altium Capital Management
New York
-$1.11M
5
SSA
Schonfeld Strategic Advisors
New York
-$1.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
26
Citadel Advisors
Florida
$1.26M +$275K +15,243 +37%
Marshall Wace
27
Marshall Wace
United Kingdom
$1.09M +$127K +7,064 +17%
Susquehanna International Group
28
Susquehanna International Group
Pennsylvania
$1.08M +$621K +34,499 +250%
BFM
29
Boothbay Fund Management
New York
$1.04M +$297K +16,500 +55%
Morgan Stanley
30
Morgan Stanley
New York
$755K +$261K +14,518 +75%
State Street
31
State Street
Massachusetts
$684K +$305K +16,938 +123%
AI
32
Atom Investors
Texas
$669K +$418K +23,185 +338%
Qube Research & Technologies (QRT)
33
Qube Research & Technologies (QRT)
United Kingdom
$559K +$452K +25,082 +114,009%
Citigroup
34
Citigroup
New York
$524K +$324K +17,983 +325%
Millennium Management
35
Millennium Management
New York
$498K +$183K +10,179 +84%
UOC
36
UBS O'Connor
Illinois
$496K -$299K -16,625 -43%
BCM
37
Bridgeway Capital Management
Texas
$471K +$139K +7,705 +57%
Northern Trust
38
Northern Trust
Illinois
$431K -$6.66K -370 -2%
JGC
39
J. Goldman & Co
New York
$401K – – –
WCM
40
Wildcat Capital Management
New York
$373K +$302K +16,756 New
Victory Capital Management
41
Victory Capital Management
Texas
$350K +$268K +14,867 +1,774%
Dimensional Fund Advisors
42
Dimensional Fund Advisors
Texas
$305K +$222K +12,302 +874%
Man Group
43
Man Group
United Kingdom
$293K +$237K +13,139 New
Connor, Clark & Lunn Investment Management (CC&L)
44
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$257K +$140K +7,789 +208%
6CM
45
683 Capital Management
New York
$256K +$207K +11,481 New
Jane Street
46
Jane Street
New York
$236K +$190K +10,576 New
DAM
47
DLD Asset Management
New York
$223K +$180K +10,000 New
Two Sigma Investments
48
Two Sigma Investments
New York
$210K +$101K +5,633 +149%
Barclays
49
Barclays
United Kingdom
$206K +$167K +9,245 New
UBS Group
50
UBS Group
Switzerland
$60.1K +$48.6K +2,699 New
1
2
3 4

PRAX Hedge Fund Activity: Q4 2023 in Review

60 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q4 2023, worth a combined $179M — down 8.5% from $196M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of PRAX and 10 opened new positions — a net loss of 14 holders — while 13 trimmed existing stakes and 32 added.

The largest buyer was Adage Capital Partners, adding an estimated $2.76M. The largest seller was Vida Ventures Advisors, exiting entirely with an estimated $2.51M sold.

  • 60 institutional investors held Praxis Precision Medicines (PRAX) as of Q4 2023, down from 74 in Q3 2023.
  • Funds reported $179M of Praxis Precision Medicines stock for Q4 2023, down 8.5% quarter-over-quarter.
  • 10 funds opened new Praxis Precision Medicines positions in Q4 2023 and 24 closed out, a net change of -14 holders.
  • The largest Praxis Precision Medicines buyer in Q4 2023 was Adage Capital Partners, an estimated $2.76M added.
  • The largest Praxis Precision Medicines seller in Q4 2023 was Vida Ventures Advisors, an estimated $2.51M sold.

Based on aggregated 13F filings for Q4 2023.